References
- Isaacson P G, Ashton-Key M. Phenotype of Hodgkin's and Reed–Sternberg cells. Lancet 1996; 347–481
- Lauritzen A F, Moller P H, Nedergaard T, Guldberg P, Hou-Jensen K, Ralfkiaer E. Apoptosis-related genes and proteins in Hodgkin's disease. APMIS 1999; 107: 636–644
- Vassallo J, Metze K, Traina F, Souza C A, Loran-Metze I. Further remarks on the expression of CD20 in classical Hodgkin's lymphomas. Haematologica 2002; 87: ELT17
- Von Wasielewski R, Mengel M, Fisher R, Hansmann M L, Hübner K, Franklin J, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997; 151: 1123–1130
- Tzarkov A, Zimpfer A, Pehrs A C, Lugli A, Went P, Mauer R, et al. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003; 16: 1141–1147
- Portlock C S, Donnelly G B, Qin J, Straus D, Yahalom J, Zelenetz A, et al. Adverse prognostic significance of CD20 positive Reed–Sternberg cells in classical Hodgkin's disease. Br J Haematol 2004; 125: 701–708
- Rassidakis G Z, Medeiros L J, Viviani S, Bonfante V, Nadali G P, Vassilakopoulos T P, et al. CD20 expression in Hodgkin and Reed–Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 2002; 20: 1278–1287
- Tzankov A, Krugmann J, Fend F, Fishhofer M, Greil R, Dirnhofer S. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clin Cancer Res 2003; 9: 1381–1386
- Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez M A, Fiumara P, et al. A pilot study of rituximab in patients with recurrent classic Hodgkin disease. Cancer 2003; 98: 310–314
- Kirchner E M, Ebsen M, Kirchner J, Theegarten D, Voigtmann R. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after rituximab monotherapy. Ann Oncol 2001; 12: 1169–1171
- Rehwald U, Schulz H, Reiser M, Sieber M, Staak J O, Morschhauser F, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101: 420–424
- Al-Ali H K, Wittekind C, Niederwieser D. Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab. Dtsch Med Wochenschr 2007; 132: 1688–1691
- Bai M C, Jiwa N M, Horstman A, Vos W, Kluin P H, Van Der Valk P, et al. Decreased expression of cellular markers in Epstein–Barr virus positive Hodgkin's disease. J Pathol 1994; 174: 49–55
- Keegan T HMK, Glaser S L, Clarke C A, Gulley M L, Craig F E, DiGiuseppe J A, et al. Epstein–Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005; 23: 7604–7613